Trends

The drugs that cost the most are the drugs we know the least about — at least when it comes...

The obesity‑drug revolution was supposed to be simple: one injection, one mechanism, one dramatic physiological outcome. But metabolic medicine rarely...

Few molecules have lived as many intellectual lives as DHEA and pregnenolone. At various moments they have been described as...

Each spring, invisible clouds drift across large sections of the United States, triggering one of the most predictable—and underestimated—public health...

Few medical symptoms generate as much immediate alarm for patients—and as much diagnostic ambiguity for clinicians—as a suddenly inflamed eye....

The most ambitious idea in modern medicine may no longer be curing disease but postponing it. Search interest around longevity...

Employer-sponsored health insurance covers roughly half of the United States population, which means that many of the country’s most consequential...

Retatrutide’s clinical profile—substantial weight loss, improved glycemic control, shifts in lipid parameters—suggests downstream effects that extend beyond obesity. In Phase...

Search patterns around functional longevity programs, mobility preservation clinics, cognitive optimization protocols, and lifespan-extension investment vehicles have intensified across healthcare...

A decision about a peptide protocol rarely begins in a clinic. It begins in a search bar, a group chat,...

The quiet revolution began in the cafeteria. Employers analyzing aggregate nutrition data alongside GLP‑1 prescription trends are discovering that pharmacologic...

Some drugs change physiology. Others change the grammar of healthcare economics. Retatrutide, the experimental triple agonist drawing sustained attention across...